Iptacopan's 82.3% haemoglobin-response rate has not reached a single GCC formulary, and fewer than 15 labs across six countries can diagnose PNH.

Anti-C5 complement inhibitors, eculizumab (Soliris) and ravulizumab (Ultomiris), both AstraZeneca/Alexion, are the GCC standard of care for PNH, covered under Saudi Arabia's national rare genetic disease programme and the UAE Ministry of Health rare-disease formulary. Access is gated by specialist-centre designation: patients with confirmed PNH, defined by elevated LDH plus a FLAER-positive clone of 10% or more, are treated only at four institutions, King Abdulaziz Medical City and King Faisal Specialist Hospital in Riyadh, Abu Dhabi's AUH, and Rashid Hospital in Dubai, concentrating the addressable population and creating a real travel burden for patients outside those cities.

Novartis's iptacopan (Fabhalta), FDA-approved in 2023 on an 82.3% haemoglobin-responder rate in APPLY-PNH, has not reached a single GCC formulary as of this writing. SFDA and MOHAP registration for novel rare-disease agents typically lags FDA/EMA approval by 12 to 24 months, and current access runs through named-patient compassionate use at select centres only. The Saudi National Rare Disease Registry tracks roughly 400 confirmed PNH cases, but consanguinity rates of 25-50% across KSA, UAE, and Qatar likely elevate true prevalence 20-30% above the global average, and fewer than 15 laboratories across all six GCC states offer FLAER flow cytometry.

Whoever registers iptacopan first captures a diagnosis-starved, under-treated GCC PNH population.

Five questions this report answers:

Q1 - Which GCC specialist centres and NPHC/MOH criteria gate access to anti-C5 therapy today?

Q2 - When will iptacopan reach SFDA/MOHAP registration and NPHC formulary listing?

Q3 - How does the FLAER diagnostic bottleneck change the addressable patient math for a new entrant?

Q4 - How does the SFDA/MOHAP registration lag affect the shift from anti-C5 IV therapy to oral inhibition?

Q5 - What would a formal switch protocol from anti-C5 IV therapy to oral Factor B inhibition require?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PNH #GCC #Iptacopan #RareDisease #ComplementInhibitor #MarketAccess

Live report page:  https://axlrx.ai/pnh/gcc/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/